| COMPANY | Linux Laboratories Pvt Ltd, Chennai (not Mumbai), specialty formulations company founded 2007 · focus on brain care (epilepsy, neuropathic pain, depression, autism), plus dermatology, cardio-diabetes and nutraceuticals |
|---|
| DEAL | US$70m of equity: a "significant minority" stake to ChrysCapital with Tata Capital Healthcare Fund III · primary plus secondary, split not disclosed · Tata Capital Healthcare Fund II exited fully at about 4x |
| PRE-DEAL REPORTS (9 SEP) | 20–25% for about ₹600 Cr (US$60–65m), from unnamed sources (Economic Times via Medical Dialogues); the final announcement gave no stake or valuation |
| OWNERSHIP BEFORE | Promoters Keerthivasan K, Ananda Kumar Sundharam and Hariharan Parameswaran 84.68%; Fund II about 15.32% |
| FINANCIALS | FY25 operating income ₹259 Cr (Medical Dialogues) or ₹285 Cr (Tofler summary) · profit ₹22–26 Cr · FY27 forecast ₹450–500 Cr revenue and ₹85–90 Cr EBITDA (unconfirmed, ET) |
| REACH | 60,000+ doctors, 1,000+ medical representatives, seven divisions, one WHO-GMP plant · 125+ brands (company) or 64+ (Medical Dialogues) |
| USE OF MONEY | Core specialties, adjacent therapies, brand acquisitions, manufacturing and R&D |
| ADVISERS | Avendus (per two outlets) or O3 Capital (one summary) for Linux; Cyril Amarchand Mangaldas for Linux; Shardul Amarchand Mangaldas for ChrysCapital |
| THE ACCESS POINT
Linux Laboratories is private. Stake and valuation were not published. Access is only through its investors' funds, open to qualified investors. |
|---|
Executive decision summary
| THE BOTTOM LINE | ChrysCapital and Tata Capital Healthcare Fund III invested US$70 million in Linux Laboratories, a Chennai maker of brain-care and other specialty medicines, in an announcement reported between 29 September and 1 October 2026. The money buys a "significant minority" stake, mixes new shares with a sale by existing holders, and lets Tata Capital Healthcare Fund II exit at about four times its cost. The stake and the valuation were not disclosed in the final announcement; the only numbers are from unnamed-source reports on 9 September that spoke of 20–25% for about ₹600 crore. FY25 revenue is given as ₹259 crore or ₹285 crore depending on the source, so the price relative to earnings cannot be fixed. The deal is the second this year in which ChrysCapital has bought into Indian pharma, after agreeing in February to buy control of Novartis India (completion reported around July by Venture Intelligence). |
|---|
| WHICH INVESTOR | The deal fits a study of private equity in branded pharma IF you want to see a minority-growth structure with a prior investor exiting.
Wait IF you need the stake, valuation or audited accounts: none was published. |
| COMFORT FIT | Minority stake = a share below 50%, so the founders keep control.
Primary and secondary = new shares for the company, and shares sold by existing investors.
CNS = central nervous system: medicines for epilepsy, pain, depression and similar conditions.
WHO-GMP = a manufacturing quality standard, so the plant can supply regulated and export markets. |
| THE RUPEIA NUMBER | 84.68% and 15.32%. The promoter and Fund II stakes before the deal, which add to exactly 100% and show that Fund II was the only outside shareholder. |
1 CLAIM REGISTER: EVIDENCE GRADING
| Claim | Source | Grade | Rupeia assessment |
|---|
| US$70m equity from ChrysCapital and Tata Capital Healthcare Fund III | Entrepreneur India; DealStreetAsia; Lapaas Voice | B | Established |
| Fund II exited about 4x | Entrepreneur India; DealStreetAsia | C | Reported by two outlets |
| 20–25% for about ₹600 Cr, pre-deal | Medical Dialogues (9 Sep), unnamed sources | D | Pre-deal report; final stake not published |
| FY25 operating income ₹259 Cr or ₹285 Cr | Medical Dialogues vs Tofler summary | D | Conflict; no audited filing opened |
| FY27 revenue ₹450–500 Cr, EBITDA ₹85–90 Cr | ET via Medical Dialogues | D | Forecast, unconfirmed |
| 125+ brands vs 64+ brands | Entrepreneur; DealStreetAsia vs Medical Dialogues | D | Conflict |
2 THE DEAL
| Item | Detail |
|---|
| Amount | US$70m of equity |
| Investors | ChrysCapital (significant minority stake) and Tata Capital Healthcare Fund III |
| Structure | Primary plus secondary from promoters and Fund II; split not disclosed (Shardul Amarchand Mangaldas note, 1 Oct) |
| Exit | Tata Capital Healthcare Fund II sells its entire holding, about 15.32% before the deal, at about 4x |
| Dates | Pre-deal report 9 Sep; company announcement 29 Sep; coverage 30 Sep to 1 Oct; advisers' notes 1 and 9 Oct |
| Use of money | Deeper penetration in core specialties, adjacent therapies, brand acquisitions, manufacturing and R&D |
| Calculation (Rupeia) | Result |
|---|
| Ownership check before the deal | 100% − 84.68% (promoters) = 15.32% (Fund II), matching Medical Dialogues |
| US$70m in rupees at ₹96.5 | About ₹676 Cr |
| Pre-deal valuation implied by ₹600 Cr for 20–25% | ₹2,400 Cr to ₹3,000 Cr |
| Valuation if US$70m bought 20–25% | US$280m to US$350m, about ₹2,700–3,400 Cr (illustration; the final stake is not published) |
| Value Fund II realised if 15.32% was sold at ₹2,400–3,000 Cr | ₹368–460 Cr, about 4x a cost of ₹92–115 Cr (illustration, assumes ₹2,400–3,000 Cr valuation) |
| RUPEIA READ
The 84.68% and 15.32% shares add to 100%, so before this deal Linux had exactly one outside shareholder, Fund II. That makes the structure unusually simple: the incoming money partly replaces the departing fund and partly goes to the company. The valuation is the missing piece. A US$70 million cheque for 20–25% implies about US$280–350 million, which is above the ₹2,400–3,000 crore implied by the pre-deal report, so either the stake or the primary size is smaller than reported. |
|---|
3 THE COMPANY AND ITS NUMBERS
| Measure | Value | Source quality |
|---|
| FY25 operating income | ₹259 Cr (Medical Dialogues); revenue ₹285 Cr against ₹250 Cr in FY24 (Tofler summary) | Conflicting |
| FY25 profit | ₹22 Cr (sign ambiguous) or ₹26 Cr against ₹17.7 Cr in FY24 | Conflicting |
| Growth | About 12.9% revenue growth (ThecompanyCheck snippet) | Snippet |
| FY27 forecast | Revenue ₹450–500 Cr; EBITDA ₹85–90 Cr | ET via Medical Dialogues; unconfirmed |
| Brands and range | 125+ brands and about 400 SKUs, or 64+ brands and about 180 products | Conflicting |
| Field force | 60,000+ doctors reached; 1,000+ medical representatives; seven divisions | Entrepreneur India |
| Plant | One WHO-GMP facility; exports and CDMO mentioned but not quantified | Entrepreneur India |
| Acquired portfolios | Biomedica, Indiabulls Pharmaceuticals, brands from Cipla and Dr Reddy's | Entrepreneur India |
| Calculation (Rupeia) | Result |
|---|
| FY25 profit margin | ₹22 Cr ÷ ₹259 Cr = 8.5%; ₹26 Cr ÷ ₹285 Cr = 9.1% |
| Revenue growth from FY24 ₹250 Cr | ₹259 Cr = +3.6%; ₹285 Cr = +14%; the 12.9% claim is close to the second |
| Growth implied by the FY27 forecast | (₹450 Cr ÷ ₹285 Cr)^0.5 = +26% a year; (₹500 Cr ÷ ₹259 Cr)^0.5 = +39% a year |
| Forecast EBITDA margin | ₹85 Cr ÷ ₹450 Cr = 18.9%; ₹90 Cr ÷ ₹500 Cr = 18% |
| Price to sales and earnings at ₹2,400–3,000 Cr | 8.4x to 11.6x FY25 revenue; 92x to 136x FY25 profit; 27x to 35x FY27 forecast EBITDA |
| Doctors per medical representative | 60,000 ÷ 1,000 = 60 |
| RUPEIA READ
The forecast would require revenue to grow by about 26–39% a year for two years from a company that grew 4–14% last year. If the ET forecast is right, the deal prices Linux at about 27 to 35 times its FY27 EBITDA; if growth stays near last year's pace, the multiple on current earnings is above 90 times. That gap is the whole valuation debate, and it cannot be resolved without audited numbers. |
|---|
4 THE INVESTORS AND THE CHRYSCAPITAL PHARMA BOOK
| Item | Detail | Source |
|---|
| ChrysCapital Fund X | US$2.2bn final close, announced 5 Nov 2025; Fund IX US$1.35bn (2022) | Search summary; Entrackr |
| Pharma and healthcare allocation | About 20–25% of Fund X, indicatively US$440–550m; Kshitij Sheth, Managing Director: "historically been overweight on pharma and healthcare" | Business Today, 22 Sep 2026 |
| Novartis India | 70.68% for about ₹1,446 Cr; agreement 19 Feb 2026 (Report 56) | Press |
| Strategy | Selective control deals alongside minority deals; Sheth: "not going to move exclusively into control deals" | Business Today |
| Tata Capital Healthcare Fund III | Also invested in Tenet Diagnostics in August 2026 (Report 58) | DealStreetAsia |
| Calculation (Rupeia) | Result |
|---|
| Fund X against Fund IX | US$2.2bn ÷ US$1.35bn − 1 = 63% larger |
| Pharma and healthcare allocation of Fund X | 20% × US$2.2bn = US$440m; 25% = US$550m |
| Two 2026 ChrysCapital pharma deals | ₹1,446 Cr (Novartis India, with partners) + about ₹676 Cr (Linux, with Tata Capital) ≈ ₹2,100 Cr |
| Linux cheque against the Fund X pharma allocation | US$70m ÷ US$440–550m = 13–16%, an upper bound because Tata Capital also invested |
Search summaries gave post-open-offer holdings of WaveRise 72.78%, Fund X 17.33% and Two Infinity 6.57% for Novartis India. These add to 96.68%, which is 70.68% plus the 26% open offer, so they describe a fully accepted offer. The actual open offer drew almost no tenders (Report 56), so those figures should not be read as holdings.
| RUPEIA READ
ChrysCapital said that it expects 20% to 25% of Fund X to go to pharma and healthcare, and in 2026 it has already written two cheques in the sector. For a Fund X investor, the interesting question is how many more deals of this size the pharma allocation can hold, and whether they are control or minority. |
|---|
5 SECTOR CONTEXT
| Datapoint | Detail | Source |
|---|
| Annual PE in Indian pharma | Rose from US$800–900m to US$1.2–1.3bn over two to three years (one firm's estimate) | Kshitij Sheth, Business Today |
| PE and VC in pharma and devices since 2016 | US$16.4bn across 303 deals; since 2021 US$10.2bn across 201 deals | EY |
| Q1 2026 pharma and healthcare deals | 78 deals, US$1.9bn, down 40% on the previous quarter | Grant Thornton Bharat |
| Reported talks | Quadria-led consortium and Samarth Lifesciences, 80–85% at about ₹4,500 Cr | Search snippet; unverified |
| Calculation (Rupeia) | Result |
|---|
| Growth in annual PE, midpoints | (1.25 ÷ 0.85) − 1 = 47% |
| Average deal size since 2016 | US$16.4bn ÷ 303 = US$54m; since 2021 US$10.2bn ÷ 201 = US$51m |
| Share of value since 2021 | US$10.2bn ÷ US$16.4bn = 62%; the share of deals is 201 ÷ 303 = 66% |
| Q1 2026 average deal | US$1.9bn ÷ 78 = US$24m |
| RUPEIA READ
The Linux cheque of US$70 million is above the sector's average deal of about US$50 million, which fits a mid-sized branded-pharma business with a clear brain-care franchise. It sits in a strong period of private-equity interest, though deal counts fell in the first quarter as big deals paused. |
|---|
6 RISKS, SCENARIOS AND CHECKLIST
| Risk | Evidence | Severity | Kill condition |
|---|
| Valuation unknown | Stake and price not published; pre-deal report conflicts with US$70m | HIGH | Entry price proves high |
| Financial disclosure | FY25 revenue ₹259 Cr vs ₹285 Cr; profit sign ambiguous | HIGH | Audited accounts show weaker figures |
| Growth forecast | FY27 forecast needs 26–39% a year | MEDIUM | Growth stays near 4–14% |
| Brand concentration | CNS-heavy domestic branded portfolio | MEDIUM | Price controls or generic competition |
| Conflicting details | Brand count, advisers and founder list differ | LOW | Corporate records differ |
| Use of money | Not quantified | MEDIUM | Brand purchases overpriced |
| Scenario | What happens | Outcome |
|---|
| Bull | Growth reaches forecast; acquisitions add brands | Strong growth platform |
| Base | Growth near 15–20%; steady margins | Moderate return |
| Bear | Growth stays low and the price proves rich | Weak return |
| Investor class | Fit | Why |
|---|
| Healthcare fund investor | WATCH | Depends on Tata Capital Healthcare Fund III's entry terms |
| Pharma sector researcher | FIT | Clear example of a minority-growth structure |
| Retail investor | NOT AVAILABLE | Private company |
Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. Open items are the stake, the valuation and audited FY25 and FY26 accounts.
7 KEY TERMS USED IN THIS REPORT
The terms below are used in this report. Each is explained in plain words.
| Term | Meaning |
|---|
| Minority stake | A holding below 50% that does not give control. |
| Primary and secondary | New shares for the company versus shares sold by existing holders. |
| CNS | Central nervous system; medicines for brain and nerve conditions. |
| WHO-GMP | A manufacturing quality standard set by the World Health Organization. |
| SKU | Stock-keeping unit: one distinct product pack. |
| CDMO | Contract development and manufacturing: making medicines for other companies. |
Frequently asked questions
What did ChrysCapital invest in?
ChrysCapital and Tata Capital Healthcare Fund III put US$70 million of equity into Linux Laboratories, a Chennai specialty pharma company, for a significant minority stake.
What stake and valuation?
The final announcement did not give them. A pre-deal report on 9 September cited unnamed sources for 20–25% at about ₹600 crore.
Who sold?
Tata Capital Healthcare Fund II exited fully, reportedly at about four times its cost. Promoters also sold some shares.
What does Linux Laboratories do?
It sells specialty formulations, led by brain-care medicines for epilepsy, pain, depression and autism, plus dermatology, cardio-diabetes and nutraceuticals.
Where is it based?
Chennai. The research brief said Mumbai, but the sources place it in Chennai.
What does Linux earn?
FY25 operating income of ₹259 crore or revenue of ₹285 crore, depending on the source, with a profit of ₹22–26 crore. No audited accounts were opened.
Source log
Entrepreneur India: Linux Labs secures US$70 Mn from ChrysCapital, Tata Capital
DealStreetAsia: Linux Laboratories raises US$70m from ChrysCap, Tata Capital Healthcare Fund III
Medical Dialogues: ChrysCapital to acquire 20–25% stake in Linux Laboratories for around ₹600 cr
Venture Intelligence: ChrysCapital to acquire 25% stake in brain-care focused Linux Labs for US$65 m
Shardul Amarchand Mangaldas: advises ChrysCapital on acquisition of stake in Linux Laboratories
SCC Online: Linux Laboratories, ChrysCapital, Tata Capital Healthcare Fund III
Lapaas Voice: Linux Laboratories US$70m deal
Business Today: Why ChrysCapital expects 20–25% of the latest US$2.2 billion fund to go to pharma and healthcare
| DISCLAIMER
This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. |
|---|